Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving
Has the success of TAVR and other interventional techniques had a negative impact on surgical valve innovation? Two surgeons shared their concerns in a new commentary.
Polymer heart valve, the first of its kind to gain commercial approval, linked to positive 1-year data
The new-look mitral valve is built using LifePolymer, a proprietary material that does not include any animal tissue. Both the frame and its leaflets are robotically generated to match each patient’s anatomy.
Effective, but not worth the cost: CEPD use during TAVR fails to make a significant difference
Cerebral embolic protection devices are proven to work. However, according to one cardiologist, they are still not consistently reducing stroke rates.
TTVR with Evoque system linked to positive real-world outcomes after 30 days
According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation.
A closer look at world’s first TAVR patient treated with new cerebral embolic protection device
The device covers three vessels at once and can be deployed through the patient's TAVR access site. Researchers shared their first-in-human experience in JACC: Case Reports.

Matt Martinez, MD, Morristown Medical Center HCM program, explains how hypertrophic cardiomyopathy patient management is changing.

Exercise plays a key part in HCM management

Matthew Martinez, MD, detailed the many ways HCM care management is changing during an exclusive interview at ASE 2023.

Permanent pacemakers after TAVR: Tracking the impact of modern self-expanding valves

Researchers explored data from more than 3,000 TAVR patients, presenting their results in JACC: Cardiovascular Interventions.

K-Clip annuloplasty system for tricuspid regurgitation by Shanghai Huihe Medical Technology Co.

Cardiologists detail world's first use of new annuloplasty system for tricuspid regurgitation

Early data suggest the new transcatheter tricuspid valve repair device could make a big impact on patient care, but additional research is still necessary.

Image of a bioprosthetic valve within the RVOT from the SCCT's congenital heart disease guidelines

SCCT shares new recommendations on use of CT imaging to guide congenital heart disease treatment

The group collaborated with two other medical societies, SCAI and CHSS, on the expert consensus document.

VDyne Valve for transcatheter tricuspid valve replacement

Cardiologists highlight early success of new TTVR system for tricuspid regurgitation

Results from a first-in-human study suggest this new-look device could provide cardiologists and their care teams with another way to treat tricuspid regurgitation in high-risk patients.

TriClip triumphs: Tricuspid edge-to-edge repair linked to strong 30-day outcomes in real-world setting

The new study, published in the Journal of the American College of Cardiology, focused on more than 500 patients treated with Abbott’s TriClip device in Europe.

doctor with overweight patient who may be treated with TAVR or surgery

TAVR vs. surgery among obese patients: What cardiologists need to know

Researchers tracked data from nearly 38,000 obese patients who underwent TAVR or SAVR, sharing their findings in a new meta-analysis.

Tracking patient outcomes after valve-in-valve TAVR, redo SAVR

It is becoming more and more important, researchers noted, to examine the lifetime management of patients who undergo aortic valve replacement.

Structural Heart Disease

At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving

Polymer heart valve, the first of its kind to gain commercial approval, linked to positive 1-year data

Effective, but not worth the cost: CEPD use during TAVR fails to make a significant difference

TTVR with Evoque system linked to positive real-world outcomes after 30 days

A closer look at world’s first TAVR patient treated with new cerebral embolic protection device